Literature DB >> 12736019

Using gray-scale and two different techniques of color Doppler sonography to detect prostate cancer.

Sergey Kravchick1, Shmuel Cytron, Ronit Peled, Alexander Altshuler, David Ben-Dor.   

Abstract

OBJECTIVES: To correlate the findings of prostate color Doppler sonography (CDS) with those of site-specific transrectal ultrasound-guided core biopsy; to evaluate the significance of two different color presets in detecting prostate cancer compared with gray-scale transrectal ultrasonography; and to compare the accuracy of conventional gray-scale transrectal ultrasound (CGS)-guided biopsy with CDS-guided biopsy.
METHODS: Seventy patients were enrolled in this prospective study. CDS was performed before biopsy. Two color presets were used: CDS-1 (high sensitivity) and CDS-2 (high specificity). The color flow was graded on a scale from 0 to 2+. At the completion of the color grading, color maps were constructed. In each case, CDS-guided biopsy was performed followed by CGS-guided biopsy (six sextant biopsies and focal lesional biopsies).
RESULTS: The cancer detection rate was 33%, 31%, and 27% for CGS-guided biopsy, CDS-1, and CDS-2, respectively. CDS-1 was more sensitive than CDS-2 (81% versus 60%) but both presets had similar specificities (79% versus 82%). CGS-guided biopsy yielded a sensitivity of 90%, a specificity of 38%, and a positive and negative predictive value of 34% and 83%, respectively. A biopsy strategy combining hypoechoicity with increased color flow increased the specificity to 97%, positive predictive value to 68%, and negative predictive value to 84%, but its sensitivity was low (18%).
CONCLUSIONS: Our experience suggests that low-velocity, high-sensitivity color is superior to all other CDS settings. The presence of focal peripheral zone hypervascularity at CDS is associated with a high likelihood of prostate cancer. However, only a combination of CDS guidance with six sextant biopsies may achieve maximal sensitivity and specificity.

Entities:  

Mesh:

Year:  2003        PMID: 12736019     DOI: 10.1016/s0090-4295(02)02520-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

Review 1.  A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer.

Authors:  Stijn W T P J Heijmink; Hilco van Moerkerk; Lambertus A L M Kiemeney; J Alfred Witjes; Ferdinand Frauscher; Jelle O Barentsz
Journal:  Eur Radiol       Date:  2006-01-04       Impact factor: 5.315

2.  Prostate biopsy: targeting cancer for detection and therapy.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2006

3.  Contrast-enhanced ultrasound imaging of prostate cancer.

Authors:  Ethan J Halpern
Journal:  Rev Urol       Date:  2006

4.  Limitations of a contemporary prostate biopsy: the blind march forward.

Authors:  John T Wei
Journal:  Urol Oncol       Date:  2010 Sep-Oct       Impact factor: 3.498

5.  Acoustic radiation force impulse imaging of human prostates: initial in vivo demonstration.

Authors:  Liang Zhai; Thomas J Polascik; Wen-Chi Foo; Stephen Rosenzweig; Mark L Palmeri; John Madden; Kathryn R Nightingale
Journal:  Ultrasound Med Biol       Date:  2011-11-21       Impact factor: 2.998

6.  Imaging in the diagnosis and management of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2004

7.  Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study.

Authors:  Kwang Suk Lee; Kyo Chul Koo; Byung Ha Chung
Journal:  World J Urol       Date:  2018-03-05       Impact factor: 4.226

8.  Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations after radical prostatectomy.

Authors:  Ryan T Schulte; David P Wood; Stephanie Daignault; Rajal B Shah; John T Wei
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

9.  The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.

Authors:  I Igerc; S Kohlfürst; H J Gallowitsch; S Matschnig; E Kresnik; I Gomez-Segovia; P Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-11       Impact factor: 9.236

10.  Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients.

Authors:  Thomas Ebenhan; Mariza Vorster; Biljana Marjanovic-Painter; Judith Wagener; Janine Suthiram; Moshe Modiselle; Brenda Mokaleng; Jan Rijn Zeevaart; Mike Sathekge
Journal:  Molecules       Date:  2015-08-14       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.